Abstract:Db/db mice exhibited low vagal activity and diabetic myocardial injury, accompanied by gut microbiota dysbiosis and gut barrier dysfunction, as well as increased lipopolysaccharide (LPS) concentrations and metabolic inflammation. Importantly, pyridostigmine could protect against diabetic myocardial injury by alleviating gut microbiota dysbiosis and gut barrier dysfunction and reducing metabolic inflammation, possibly by inhibiting the LPS‐induced activation of the ERK/Egr‐1 pathway. Moreover, acetylcholine ameliorated high‐glucose (HG) and LPS‐induced cardiomyocytes injury by inhibiting the ERK/Egr‐1 pathway and inflammation through α7nAChR. Autonomic imbalance and metabolic inflammation are important pathological processes in diabetic cardiomyopathy. Gut microbiota dysbiosis and increased levels of bacterial component lipopolysaccharide (LPS) are associated with diabetic myocardial injury, but the mechanism by which gut microbes affect metabolic inflammation and cardiac injury remains unclear. We determined whether pyridostigmine (PYR), which inhibits cholinesterase to improve vagal activity, could regulate the disordered gut microbiota and attenuate gut barrier dysfunction, metabolic endotoxemia, and inflammation in diabetes. Db/db mice exhibited high blood glucose levels, insulin resistance, low vagal activity, and diabetic myocardial injury. Db/db mice also exhibited gut microbiota perturbations and subsequent disruption of gut barrier function, resulting in an influx of LPS, metabolic endotoxemia, and inflammation. PYR ameliorated the dysregulated glucose and lipid metabolism, modulated the overall structure of the gut microbiota, selectively enhanced the abundance of anti‐inflammatory bacteria, and reduced the abundance of proinflammatory and potentially pathogenic bacteria in db/db mice. Importantly, PYR enhanced vagal activity, restored gut microbiota homeostasis, and alleviated gut barrier dysfunction. Therefore, the LPS‐induced extracellular signal‐regulated kinase (ERK)/early growth response‐1 (Egr‐1) pathway and consequent metabolic inflammation were inhibited, and eventually, cardiac hypertrophy, fibrosis, oxidative stress, and dysfunction were ameliorated in db/db mice. In vitro cardiomyocyte injury was induced by exposing primary neonatal rat ventricular cardiomyocytes to high glucose (HG) and LPS. In vitro analyses showed that HG + LPS induced ERK1/2 phosphorylation, Egr‐1 expression, inflammation, and cell apoptosis, which were inhibited by acetylcholine (ACh). Alpha 7 nicotinic ACh receptor but not muscarinic 2 ACh receptor plays an important role in ACh‐mediated anti‐inflammatory effects and inhibiting the ERK/Egr‐1 pathway in HG + LPS‐administered neonatal rat ventricular cardiomyocytes. PYR and ACh ameliorated diabetic myocardial injury by inhibiting the LPS‐induced ERK/Egr‐1 pathway and metabolic inflammation. The vagus–gut–heart axis has provided new insights into the complex mechanisms of diabetes and offers novel therapeutic targets.

Long-term administration of pyridostigmine attenuates pressure overload-induced cardiac hypertrophy by inhibiting calcineurin signalling.

Pyridostigmine Ameliorates Cardiac Remodeling Induced by Myocardial Infarction Via Inhibition of the Transforming Growth Factor-β1/TGF-β1–Activated Kinase Pathway

Pyridostigmine attenuates hypertension by inhibiting activation of the renin-angiotensin system in the hypothalamic paraventricular nucleus

Pyridostigmine Protects Against Cardiomyopathy Associated with Adipose Tissue Browning and Improvement of Vagal Activity in High-Fat Diet Rats.

Effects of combination of irbesartan and perindopril on calcineurin expression and sarcoplasmic reticulum Ca 2+ -ATPase activity in rat cardiac pressure-overload hypertrophy

Modulation of left ventricular hypertrophy in spontaneously hypertensive rats by acetylcholinesterase and ACE inhibitors: physiological, biochemical, and proteomic studies

Pyridostigmine Prevents Peripheral Vascular Endothelial Dysfunction in Rats with Myocardial Infarction

Chronic acetylcholinesterase inhibition reduces the effects of physical training on ventricular contractility and coronary bed reactivity in hypertensive rats

Endogenous Ghrelin Attenuates Pressure Overload-Induced Cardiac Hypertrophy Via A Cholinergic Anti-Inflammatory Pathway

Long-Term Activation of Adenosine Monophosphate-Activated Protein Kinase Attenuates Pressure-Overload-Induced Cardiac Hypertrophy

Cholinergic drugs reduce metabolic inflammation and diabetic myocardial injury by regulating the gut bacterial component lipopolysaccharide‐induced ERK/Egr‐1 pathway

Pyridostigmine Protects Against Diabetic Cardiomyopathy by Regulating Vagal Activity, Gut Microbiota, and Branched-Chain Amino Acid Catabolism in Diabetic Mice

Pyridostigmine Protects Against Diabetic Cardiomyopathy by Regulating Gut Microbiota and Branched-Chain Amino Acid Catabolism to Attenuate Mitochondria Dysfunction

Pyridostigmine Alleviates Cardiac Dysfunction Via Improving Mitochondrial Cristae Shape in a Mouse Model of Metabolic Syndrome.

Pyridostigmine Improved Macrophage Polarization and Cardiac Fibrosis Induced by Isoproterenol in Mice

Inhibiting glycosphingolipids alleviates cardiac hypertrophy by reducing reactive oxygen species and restoring autophagic homeostasis

[Oxidative Stress and Calcium/calmodulin-Dependent Protein Kinase II Contribute to the Development of Sustained Β Adrenergic Receptor-Stimulated Cardiac Hypertrophy in Rats].

Β-Adrenergic Activation May Promote Myosin Light Chain Kinase Degradation Through Calpain in Pressure Overload-Induced Cardiac Hypertrophy: Β-Adrenergic Activation Results in MLCK Degradation.

Pyridostigmine regulates glucose metabolism and mitochondrial homeostasis to reduce myocardial vulnerability to injury in diabetic mice.

Effect of Antioxidant on Monocyte Chemoattractant Protein-1 in Pressure Overload Induced Hypertrophied Myocardium in Rats

Cholinergic Stimulation Exerts Cardioprotective Effects and Alleviates Renal Inflammatory Responses after Acute Myocardial Infarction in Spontaneous Hypertensive Rats (SHRs)